Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2026 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
June 04, 2026 07:00 ET | Source: LeonaBio, Inc.

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

BOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...
June 04, 2026 07:00 ET | Source: GH Research PLC

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance...
June 03, 2026 06:05 ET | Source: MannKind

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
June 03, 2026 04:30 ET | Source: Custom Market Insights

[Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, June 03, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “CRISPR-based Gene Editing Market Size, Trends and Insights By Product (Kits and...
June 02, 2026 11:23 ET | Source: Exousia Pro, Inc.

NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization

NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
June 02, 2026 09:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO).
June 02, 2026 07:30 ET | Source: Pluri Inc.

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Two regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026.
June 02, 2026 06:30 ET | Source: Merakris Therapeutics

FDA Grants Fast Track Designation to Merakris’ MTX-001, Opening Potential Accelerated Path to Market for Venous Leg Ulcer Therapy

Merakris announces FDA Fast Track designation for MTX-001, its lead biologic candidate for the treatment of venous leg ulcers.
June 02, 2026 02:00 ET | Source: Lucera GmbH

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient Well-established pharmaceutical technology...